0 199

Cited 25 times in

Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma

DC Field Value Language
dc.contributor.author조병철-
dc.date.accessioned2018-03-26T16:56:50Z-
dc.date.available2018-03-26T16:56:50Z-
dc.date.issued2015-
dc.identifier.issn0008-543X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/156989-
dc.description.abstractBACKGROUND: The objective of this study was to evaluate the efficacy and safety of dovitinib in patients with adenoid cystic carcinoma (ACC). METHODS: ACC patients with documented disease progression within the past 12 months were eligible. Patients received oral dovitinib (500 mg once daily for 5 consecutive days followed by a 2-day rest every week) until disease progression or unacceptable toxicities. The primary endpoint was the probability of 4-month progression-free survival (PFS). Metabolic response was evaluated with positron emission tomography (PET)/computed tomography (CT) scans performed at the baseline and after 8 weeks of treatment. RESULTS: Between September 2011 and April 2013, 32 patients with metastatic and/or unresectable ACC were enrolled in this prospective, multicenter trial. The 4-month PFS probability was 80.4%, and the median PFS was 6.0 months (95% confidence interval, 4.4-7.6 months). Tumor shrinkage was observed in 22 patients (68.8%), and 1 patient had a confirmed partial response. The disease control rate was 96.9%. Among 26 patients with PET/CT scans both before and after treatment (at 8 weeks), the metabolic activity of ACC was reduced in 13 patients (50.0%), and 5 patients (19.2%) achieved a metabolic partial response, which was defined as a ≥25% reduction in maximum standardized uptake values. Common grade 3 and 4 adverse events were asthenia (50.0%) and neutropenia (25.0%). CONCLUSIONS: Dovitinib shows modest antitumor activity in the treatment of ACC.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherWiley-
dc.relation.isPartOfCANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Agents/therapeutic use*-
dc.subject.MESHBenzimidazoles/therapeutic use*-
dc.subject.MESHCarcinoma, Adenoid Cystic/drug therapy*-
dc.subject.MESHCarcinoma, Adenoid Cystic/mortality-
dc.subject.MESHCarcinoma, Adenoid Cystic/pathology-
dc.subject.MESHFemale-
dc.subject.MESHHead and Neck Neoplasms/drug therapy*-
dc.subject.MESHHead and Neck Neoplasms/mortality-
dc.subject.MESHHead and Neck Neoplasms/pathology-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHQuinolones/therapeutic use*-
dc.subject.MESHRepublic of Korea/epidemiology-
dc.subject.MESHSalivary Gland Neoplasms/drug therapy-
dc.subject.MESHSalivary Gland Neoplasms/mortality-
dc.subject.MESHSalivary Gland Neoplasms/pathology-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHYoung Adult-
dc.titlePhase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorBhumsuk Keam-
dc.contributor.googleauthorSung-Bae Kim-
dc.contributor.googleauthorSeong Hoon Shin-
dc.contributor.googleauthorByoung Chul Cho-
dc.contributor.googleauthorKeun-Wook Lee-
dc.contributor.googleauthorMin Kyoung Kim-
dc.contributor.googleauthorHwan-Jung Yun-
dc.contributor.googleauthorSe-Hoon Lee-
dc.contributor.googleauthorDok Hyun Yoon-
dc.contributor.googleauthorYung-Jue Bang-
dc.identifier.doi10.1002/cncr.29401-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ00434-
dc.identifier.eissn1097-0142-
dc.identifier.pmid25903089-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1002/cncr.29401/abstract-
dc.subject.keywordadenoid cystic carcinoma-
dc.subject.keywordclinical trial-
dc.subject.keyworddovitinib-
dc.subject.keyworddovitinib (TKI258)-
dc.subject.keywordfibroblast growth factor receptor (FGFR)-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.citation.volume121-
dc.citation.number15-
dc.citation.startPage2612-
dc.citation.endPage2617-
dc.identifier.bibliographicCitationCANCER, Vol.121(15) : 2612-2617, 2015-
dc.identifier.rimsid41298-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.